SOSEI AND VECTURA ANNOUNCE COMPLETION OF NVA237 TRIAL

A A

Sosei and Vectura Group have announced that their collaborative product, NVA237, a novel inhaled once-daily treatment for chronic obstructive pulmonary disease (COPD), had successfully completed a Phase IIb multiple dose-ranging clinical trial.

NVA237 is being developed and commercialized by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol, under the terms of a global licence agreement signed in April 2005.

The outcome of the study supports the progression of NVA237 and Novartis are proceeding as planned with the development program.